Based on in vitro assessment, luliconazole at therapeutics doses, particularly when
applied to patients with moderate to severe tinea cruris, may inhibit the activity of
CYP3A4; however no in vivo drug interaction trials have been conducted to
evaluate the effect of luliconazole on drugs that are substrates of CYP3A4.
Saccharomyces boulardii4
Antifungal agents may diminish the therapeutics effect of Saccharomyces
boulardii